167 related articles for article (PubMed ID: 16406889)
1. Testosterone loss and estradiol administration modify memory in men.
Beer TM; Bland LB; Bussiere JR; Neiss MB; Wersinger EM; Garzotto M; Ryan CW; Janowsky JS
J Urol; 2006 Jan; 175(1):130-5. PubMed ID: 16406889
[TBL] [Abstract][Full Text] [Related]
2. Estradiol and cognition during androgen deprivation in men with prostate carcinoma.
Salminen EK; Portin RI; Koskinen AI; Helenius HY; Nurmi MJ
Cancer; 2005 Apr; 103(7):1381-7. PubMed ID: 15717315
[TBL] [Abstract][Full Text] [Related]
3. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men.
Almeida OP; Waterreus A; Spry N; Flicker L; Martins RN
Psychoneuroendocrinology; 2004 Sep; 29(8):1071-81. PubMed ID: 15219659
[TBL] [Abstract][Full Text] [Related]
4. The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer.
Taxel P; Luthra P; Fall PM; Dauser D
Aging Male; 2008 Jun; 11(2):71-5. PubMed ID: 18570058
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy for prostate cancer: effects on hand function.
Soyupek F; Soyupek S; Perk H; Ozorak A
Urol Oncol; 2008; 26(2):141-6. PubMed ID: 18312932
[TBL] [Abstract][Full Text] [Related]
6. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
Joly F; Alibhai SM; Galica J; Park A; Yi QL; Wagner L; Tannock IF
J Urol; 2006 Dec; 176(6 Pt 1):2443-7. PubMed ID: 17085125
[TBL] [Abstract][Full Text] [Related]
7. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
8. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
9. [Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate].
Nedelec C; Ragot S; Irani J; Pires C; Gil R; Doré B
Prog Urol; 2009 Jan; 19(1):47-53. PubMed ID: 19135642
[TBL] [Abstract][Full Text] [Related]
10. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
11. Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer.
Timilshina N; Breunis H; Alibhai SM
J Urol; 2012 Dec; 188(6):2183-8. PubMed ID: 23083859
[TBL] [Abstract][Full Text] [Related]
12. Associations between serum testosterone fall and cognitive function in prostate cancer patients.
Salminen EK; Portin RI; Koskinen A; Helenius H; Nurmi M
Clin Cancer Res; 2004 Nov; 10(22):7575-82. PubMed ID: 15569988
[TBL] [Abstract][Full Text] [Related]
13. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.
Jenkins VA; Bloomfield DJ; Shilling VM; Edginton TL
BJU Int; 2005 Jul; 96(1):48-53. PubMed ID: 15963119
[TBL] [Abstract][Full Text] [Related]
14. Levels of sex hormones have limited effect on cognition in older men with or without prostate cancer.
Alibhai SM; Mahmoud S; Hussain F; Naglie G; Tannock I; Tomlinson G; Fleshner N; Krahn M; Warde P; Klotz L; Breunis H; Leach M; Canning SD
Crit Rev Oncol Hematol; 2010 Feb; 73(2):167-75. PubMed ID: 19346137
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
Morote J; Orsola A; Abascal JM; Planas J; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
[TBL] [Abstract][Full Text] [Related]
16. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
17. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy.
Maggio M; Blackford A; Taub D; Carducci M; Ble A; Metter EJ; Braga-Basaria M; Dobs A; Basaria S
J Androl; 2006; 27(6):725-8. PubMed ID: 16775253
[TBL] [Abstract][Full Text] [Related]
18. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in hormonal therapy for advanced prostate cancer.
Daskivich TJ; Oh WK
Curr Opin Urol; 2006 May; 16(3):173-8. PubMed ID: 16679855
[TBL] [Abstract][Full Text] [Related]
20. Complications of androgen deprivation therapy in prostate cancer.
Schwandt A; Garcia JA
Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
